Table 2.
Efficacy of clinical trials targeting HER2-positive mCRC in which NGS was performed.
| Clinical Trial | n | PFS | ||
|---|---|---|---|---|
| HERACLES [29,31] | (weeks) | |||
| qPCR (tissue) | CN ≥ 9.45 | 18 | 29 | HR 0.67 (95% CI 0.6–0.8), p = 0.0001 |
| CN < 9.45 | 9 | 16 | ||
| NGS (plasma) | ApCN ≥ 25.82 | 15 | 22.5 | p = 0.0347 |
| ApCN < 25.82 | 13 | 14.8 | ||
| TRIUMPH [14] | (months) | |||
| NGS (tissue) | CN ≥ 68.7 | 9 | 6.2 | HR 0.28 (95% CI 0.11–0.74) |
| CN < 68.7 | 20 | 2.2 | ||
| NGS (plasma) | ApCN ≥ 16.7 | 13 | 5.6 | HR 0.14 (95% CI 0.05–0.39) |
| ApCN < 16.7 | 16 | 1.6 | ||
| DESTINY-CRC01 [38] | (months) | |||
| NGS (plasma) | ApCN ≥ 30.9 | 24 | 10.9 | |
| ApCN < 30.9 | 28 | 4.1 |
Abbreviations: NGS, next-generation sequencing; CN, copy number; ApCN, adjusted plasma copy number; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; mCRC, metastatic colorectal cancer.